Regenerative Medicine Market (By Product: Gene Therapies, Cell Therapies, Tissue-Engineering, Small Molecules & Biologics; By Material: Synthetic material, Biologically derived material, Genetically Engineered Material, Pharmaceutical; By Application: Wound Care, Musculoskeletal, Ophthalmology, Oncology, Cardiovascular, Dermatology, Neurology, Others; By End User) - Global Industry Analysis, Market Size, Share, Growth, Trends, Regional Outlook and Forecasts 2024 - 2033
The global regenerative medicine market size was valued at USD 29.42 billion in 2023 and it is predicted to be worth around USD 154.05 billion by 2033 with a remarkable CAGR of 18% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. regenerative medicine market size was valued at USD 13.44 billion in 2023 and it is expected to be worth around USD 83.26 billion by 2033 with a CAGR of 20% from 2024 to 2033.
Geographically, regenerative medicine market is conquered by North America owing to high incidence of chronic diseases and presence of sophisticated healthcare framework. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing healthcare expenditure and growing investment by major manufactures to launch new products. The North American regenerative medicine market is in its growing phase and is expected to exhibit high potential in future, as most of the therapies are in the 3rd phase of clinical trials. This shows the intervention of companies for commercialization of regenerative medicine products. Favorable regulatory and reimbursement policies for tissue engineering exhibit interest of the government authorities in fulfilling the growth in need of regenerative products. However, stringent regulatory policies pertaining to stem cell technologies have posed major challenges for the adoption of embryonic stem cells, owing to ethical issues and controversies regarding its source; thereby, restricting the market growth.
These challenges are expected to be resolved in future, as companies and research institutes provide novel therapies, which are anticipated to replace embryonic stem cells for various applications. In addition, technology advancement for tissue and organ transplantation, emerging technologies, and focus on stem cells, expand the growth of the market. Among the countries in North America, the U.S. is the largest contributor to the market growth, Canada offers a productive location, and Mexico has a well-established R&D infrastructure.
The Asia-Pacific region includes China, Japan, India, Indonesia, Myanmar, Thailand, Australia, New Zealand, and other countries in the Pacific Rim. It influences the market substantially due to their varied culture and demography. High incidence rate of unintentional trauma injuries has triggered the growth of the regenerative medicine market. Global players have focused on provision of cost-effective therapies to patients and adoption of novel stem cells-based technologies useful in the development of products for the treatment of diseases. This is primarily due to the increase in incidence of injuries and growth in geriatric population. Lack of awareness about regenerative medicine and stringent growth regulations hamper the market growth.
Among Asia-Pacific countries, Japan has the largest influence on pharmaceutical and biotechnology markets, while China is the fastest growing economy. Moreover, Australia has higher healthcare costs as compared to other countries of the Asia-Pacific region due to increase in geriatric patients. Rest of the region provides substantial growth opportunities to the market players.
Regenerative Medicine Market Size, By Region ($ Million) 2019-2022
Region | 2019 | 2020 | 2021 | 2022 |
North America | 4,493.2 | 5,990.8 | 9,835.4 | 11,836.5 |
Europe | 3,091.9 | 4,101.7 | 6,700.1 | 8,022.7 |
Asia Pacific | 1,121.2 | 1,549.0 | 2,635.1 | 3,286.0 |
LAMEA | 361.1 | 508.8 | 877.3 | 1,102.9 |
Key market Insights:
Stem cell therapy is one of the most revolutionary applications of regenerative medicine in the real-world scenario. Stem cell therapy encourages the repair response of ailing, dysfunctional or wounded tissue by means of stem cells or their by products. It is the next big thing in organ transplantation and makes use of cells in the place of donor organs, that are limited in stock. Scientists cultivate stem cells in a laboratory. These stem cells are operated to specialize into particular cells, such as blood cells, heart muscle or nerve cells. The specific cells can then be implanted into an individual. Stem cells have the capability to build all tissue in the human body, therefore have great possibility for future healing uses in tissue repair and regeneration.
Report Highlights | Details |
Market Size | USD 154.05 Billion by 2033 |
Growth Rate | CAGR of 18% from 2024 to 2033 |
Largest Market | North America |
Fastest Growing Market | Asia Pacific |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Product, By Material, By Application, By End User, and Region |
Companies Mentioned | Integra LifeSciences Corporation, Aspect Biosystems, Amgen, Inc., Medtronic plc, AstraZeneca, Novartis AG, Smith & Nephew plc, MiMedx Group, Shenzhen SibionoGeneTech Co., Ltd., and Baxter |
HIGH ADOPTION OF STEM CELL TECHNOLOGY
EMERGING APPLICATION OF NANOTECHNOLOGY
INCREASING PREVALENCE OF CHRONIC DISEASES AND TRAUMA EMERGENCIES
ADVANCEMENTS IN MEDICAL EQUIPMENT TECHNOLOGIES
Market Restraints
ETHICAL HURDLES
COSTLY TREATMENT ASSOCIATED WITH REGENERATIVE MEDICINE
Market Opportunities
LUCRATIVE OPPORTUNITIES OF NOVEL STEM CELL TECHNOLOGIES
INCREASE IN POTENTIAL IN EMERGING ECONOMIES
GROWTH IN NEED OF REGENERATIVE MEDICINE IN ORGAN TRANSPLANTATION
Tissue-Engineering Segment Reported Foremost Market Stake in 2023
Tissue-Engineering segment recorded the prime market share in the global regenerative medicine market in 2023. The key reason for the hefty share of the tissue-engineering segment is multiple advantages such as ability to replace a defective structure with an entirely living structure and potential in developing treatments for previously untreatable medical conditions. Moreover, high investment in research and development for developing effective treatments, and constant launch of new and effective products are expected to boost the demand in tissue engineering segment.
The stem cell therapies segment is projected grow at the highest CAGR during the forecast period mainly due to increasing popularity of stem cell related treatment options and high investment by major manufacturers. Other factors responsible for high growth of stem cells therapy segment are increasing geriatric population, and increasing trauma cases worldwide.
Regenerative Medicine Market Size, By Product ($ Million), 2019 to 2022
Product | 2019 | 2020 | 2021 | 2022 |
Cell Therapy | 5,288.9 | 7,051.7 | 11,577.1 | 13,932.5 |
Gene Therapy | 739.9 | 993.4 | 1,642.5 | 1,990.5 |
Tissue Engineering | 2,538.2 | 3,421.6 | 5,679.6 | 6,910.7 |
Small Molecules & Biologics | 500.4 | 683.5 | 1,148.9 | 1,414.4 |
Musculoskeletal Applications are Projected to Dominate the Regenerative Medicine Market Revenue
Regenerative medicine, specifically cellular therapy, is a rapidly emerging field that is being explored as a possibility for the repair of function in numerous disease areas including musculoskeletal ailments. High research and development activity in use of regenerative medicine for the treatment of musculoskeletal disorders is the major reason for the high revenue share of regenerative medicines.
Oncology segment will hold a significant share in the global regenerative medicine market mainly due to the high incidence of cancer globally and increasing demand for development of new technologies for the treatment of cancer.
Regenerative Medicine Market Size, By Application ($ Million), 2019-2022
Application | 2019 | 2020 | 2021 | 2022 |
Cardiovascular | 403.5 | 547.2 | 913.7 | 1,118.4 |
Oncology | 1,088.1 | 1,459.5 | 2,410.6 | 2,918.5 |
Dermatology | 591.6 | 788.1 | 1,292.5 | 1,553.9 |
Musculoskeletal | 3,033.8 | 4,053.1 | 6,667.5 | 8,040.1 |
Wound healing | 2,575.1 | 3,461.0 | 5,727.8 | 6,948.6 |
Ophthalmology | 496.4 | 658.6 | 1,075.8 | 1,288.2 |
Neurology | 275.8 | 371.8 | 617.2 | 751.0 |
Others | 603.0 | 811.1 | 1,343.0 | 1,629.5 |
The companies focusing on research and development are expected to lead the global regenerative medicine market. Leading competitors contending in global regenerative medicine market are as follows:
In order to better recognize the current status of regenerative medicine, and policies adopted by the foremost countries, Precedence Research predicted the future evolution of the regenerative medicine market. This research study bids qualitative and quantitative insights on regenerative medicine market and assessment of market size and growth trend for potential market segments.
By Product
By Material
By Application
By End User
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Regenerative Medicine Market
5.1. COVID-19 Landscape: Regenerative Medicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Regenerative Medicine Market, By Product
8.1. Regenerative Medicine Market, by Product, 2024-2033
8.1.1. Gene Therapies
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Cell Therapies
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Tissue-Engineering
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Small Molecules & Biologics
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Regenerative Medicine Market, By Material
9.1. Regenerative Medicine Market, by Material, 2024-2033
9.1.1. Synthetic material
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Biologically derived material
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Genetically Engineered Material
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Pharmaceutical
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Regenerative Medicine Market, By Application
10.1. Regenerative Medicine Market, by Application, 2024-2033
10.1.1. Wound Care
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Musculoskeletal
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Ophthalmology
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Oncology
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Cardiovascular
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Dermatology
10.1.6.1. Market Revenue and Forecast (2021-2033)
10.1.7. Neurology
10.1.7.1. Market Revenue and Forecast (2021-2033)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Regenerative Medicine Market, By End User
11.1. Regenerative Medicine Market, by End User, 2024-2033
11.1.1. Hospitals & Clinics
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Commercial Industries
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Government & Academic Research Institutes
11.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Regenerative Medicine Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.2. Market Revenue and Forecast, by Material (2021-2033)
12.1.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.4. Market Revenue and Forecast, by End User (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Material (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Material (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.1.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.2. Market Revenue and Forecast, by Material (2021-2033)
12.2.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Material (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Material (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Material (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Material (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.2.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.2. Market Revenue and Forecast, by Material (2021-2033)
12.3.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Material (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Material (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Material (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Material (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.3.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.2. Market Revenue and Forecast, by Material (2021-2033)
12.4.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Material (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Material (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.6.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Material (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.7.4. Market Revenue and Forecast, by End User (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Material (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2033)
12.4.8.4. Market Revenue and Forecast, by End User (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.2. Market Revenue and Forecast, by Material (2021-2033)
12.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Material (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.5.4. Market Revenue and Forecast, by End User (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Material (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2033)
12.5.6.4. Market Revenue and Forecast, by End User (2021-2033)
Chapter 13. Company Profiles
13.1. Integra LifeSciences Corporation
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Aspect Biosystems
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Amgen, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Medtronic plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Novartis AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Smith & Nephew plc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. MiMedx Group
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Shenzhen SibionoGeneTech Co., Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Baxter
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client